back to US directory
us clinical guidance

Evaluation of abnormal liver chemistries

ACG-based confirmation, injury-pattern classification, etiologic evaluation and urgency assessment for abnormal aminotransferases, alkaline phosphatase or bilirubin.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with incidentally or clinically detected abnormal alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase or bilirubin. These are liver chemistries rather than direct measures of liver function. Acute liver failure, decompensated cirrhosis, pregnancy-specific disease and pediatric reference intervals require separate pathways.
sources for this section:acg-abnormal-liver-chemistries-2017

The Bottom Line

  • Confirm the abnormality and review the laboratory reference range and prior results, but do not delay urgent assessment when jaundice, coagulopathy or acute severe illness is present.
  • Classify the pattern as predominantly hepatocellular, cholestatic or mixed from aminotransferases and alkaline phosphatase relative to their upper limits of normal; fractionate bilirubin and confirm hepatic alkaline phosphatase when necessary.
  • For hepatocellular injury, evaluate viral hepatitis, MASLD, alcohol, autoimmune hepatitis, hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency and drug or supplement injury according to degree, age and context.
  • For cholestatic injury, obtain biliary imaging and evaluate primary biliary cholangitis and primary sclerosing cholangitis when appropriate rather than treating an isolated alkaline-phosphatase result empirically.
  • Take a complete prescription, over-the-counter, herbal, bodybuilding and dietary-supplement history because drug-induced liver injury is a diagnosis requiring exclusion of competing causes.
sources for this section:acg-abnormal-liver-chemistries-2017

Practical clinical workflow

1
Repeat or confirm the relevant panel when clinically safe, assess INR, albumin and platelet count for severity and chronicity, and compare with baseline, symptoms, alcohol and metabolic risk.
2
Calculate the biochemical injury pattern, fractionate bilirubin, confirm alkaline-phosphatase origin with gamma-glutamyl transferase when indicated and use ultrasound early for cholestasis or right-upper-quadrant features.
3
Order etiologic tests targeted to pattern and probability, including viral serology, iron studies, autoimmune markers and age-appropriate inherited-disease testing; avoid indiscriminate panels without interpretation.
4
Stop a plausible hepatotoxic nonessential agent when safe, document timing and use an authoritative injury resource; do not rechallenge a suspect drug casually.
5
Refer persistent unexplained abnormalities, significant fibrosis risk or suspected chronic liver disease to hepatology; consider biopsy only when serology and imaging do not establish diagnosis or multiple processes remain possible.
sources for this section:acg-abnormal-liver-chemistries-2017

Safety boundaries and escalation

  • New encephalopathy with coagulopathy in a patient without established cirrhosis suggests acute liver failure and requires immediate transfer to a center with transplant capability.
  • Jaundice with fever and right-upper-quadrant pain can indicate ascending cholangitis and needs emergency biliary and antimicrobial management.
  • Very high aminotransferases require rapid evaluation for ischemia, acetaminophen toxicity and acute viral or autoimmune hepatitis; obtain an acetaminophen level when the history could be incomplete.
  • Do not interpret a normal aminotransferase value as excluding cirrhosis, and do not use albumin or INR changes without considering nutrition, anticoagulation and systemic illness.
sources for this section:acg-abnormal-liver-chemistries-2017

Localization

US laboratory reference intervals and testing access vary; follow ACG evaluation categories together with current AASLD disease-specific guidance and FDA drug safety.
sources for this section:acg-abnormal-liver-chemistries-2017

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American College of GastroenterologyACG Clinical Guideline: Evaluation of Abnormal Liver ChemistriesDOI 10.1038/ajg.2016.517 路 published 2017-01-01 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.